Honda S, Tomiyama Y, Pelletier A J, Annis D, Honda Y, Orchekowski R, Ruggeri Z, Kunicki T J
Roon Research Center for Arteriosclerosis and Thrombosis, Scripps Research Institute, La Jolla, California 92037, USA.
J Biol Chem. 1995 May 19;270(20):11947-54. doi: 10.1074/jbc.270.20.11947.
Changes in ligand binding ability of the integrin alpha IIb beta 3 can be monitored by the concomitant expression of ligand-inducible binding sites (LIBS). A new LIBS, the hexapeptide sequence GPNICT (residues 1-6) at the amino terminus of beta 3 recognized by the murine monoclonal antibody (mAb) AP5, is sensitive both to the binding of ligand and to micromolar differences in divalent cation levels. Calcium or magnesium can completely inhibit the binding of AP5 to alpha IIb beta 3 on platelets, with ID50 values of 80 and 1500 microM, respectively. The inhibitory effect of calcium plus magnesium is cumulative. In the presence of 1 mM calcium plus 1 mM magnesium, the peptide RGDW overcomes this inhibition and induces maximal binding of AP5. Maximal AP5 binding is also induced by a molar excess of EDTA. The unique location of the AP5 LIBS was determined by comparing the binding of LIBS-specific mAb to recombinant human-Xenopus beta 3 chimeras produced in a baculovirus expression system. AP5 defines one region at the amino terminus beta 3 1-6. A second region, defined by mAb D3GP3, is probably located within beta 3 422-490, confirming the finding of Kouns et al. (Kouns, W. C., Newman, P.J., Puckett, K. J., Miller, A. A., Wall, C. D., Fox, C. F., Seyer, J. M., and Jennings, L. K. (1991) Blood 78, 3215-3223). The third region, encompassing at most residues 490-690, and perhaps more precisely located within 602-690 (Du X., Gu, M., Weise, J. W., Nagaswami, C., Bennett, J. S., Bowditch, R., and Ginsberg, M. H. (1993) J. Biol. Chem. 268, 23087-23092), is recognized by the four mAb, anti-LIBS2, anti-LIBS3, anti-LIBS6, and P41. Since its exposure is uniquely regulated by both divalent cations and ligand, the amino terminus of beta 3 may be involved in control of ligand binding by divalent cation mobilization.
整联蛋白αIIbβ3配体结合能力的变化可通过配体诱导结合位点(LIBS)的伴随表达来监测。一种新的LIBS,即β3氨基末端的六肽序列GPNICT(第1 - 6位残基),可被鼠单克隆抗体(mAb)AP5识别,它对配体结合以及二价阳离子水平的微摩尔差异均敏感。钙或镁可完全抑制AP5与血小板上αIIbβ3的结合,其半数抑制浓度(ID50)值分别为80和1500μM。钙加镁的抑制作用是累积性的。在存在1 mM钙加1 mM镁的情况下,肽RGDW可克服这种抑制并诱导AP5的最大结合。过量的EDTA也可诱导AP5的最大结合。通过比较LIBS特异性单克隆抗体与在杆状病毒表达系统中产生的重组人 - 非洲爪蟾β3嵌合体的结合,确定了AP5 LIBS的独特位置。AP5确定了β3 1 - 6氨基末端的一个区域。由单克隆抗体D3GP3定义的第二个区域可能位于β3 422 - 490内,这证实了Kouns等人的发现(Kouns, W. C., Newman, P.J., Puckett, K. J., Miller, A. A., Wall, C. D., Fox, C. F., Seyer, J. M., and Jennings, L. K. (1991) Blood 78, 3215 - 3223)。第三个区域,最多包含残基490 - 690,可能更精确地位于602 - 690内(Du X., Gu, M., Weise, J. W., Nagaswami, C., Bennett, J. S., Bowditch, R., and Ginsberg, M. H. (1993) J. Biol. Chem. 268, 23087 - 23092),可被四种单克隆抗体,即抗 - LIBS2、抗 - LIBS3、抗 - LIBS6和P41识别。由于其暴露受到二价阳离子和配体的独特调节,β3的氨基末端可能通过二价阳离子动员参与配体结合的控制。